From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D015762:2-Chloroadenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D017338:Cladribine; D003839:Deoxyadenosines / Q000627:therapeutic use; D015507:Drugs, Investigational; D004864:Equipment and Supplies; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy; D011358:Product Surveillance, Postmarketing; D017828:Rifabutin; D012294:Rifamycins / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000806:Angiotensin-Converting Enzyme Inhibitors; D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D003839:Deoxyadenosines; D015507:Drugs, Investigational; D012294:Rifamycins; D015762:2-Chloroadenosine; D017828:Rifabutin; D017338:Cladribine